CTLA4 and cervical carcinoma: Preliminary results from the ongoing phase I/II trial of balstilimab (anti-PD-1) as monotherapy or in combination with zalifrelimab (anti-CTLA-4) in patients with metastatic or locally advanced cervical cancer were also presented [49,50].